{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:12:09Z","timestamp":1790881929346,"version":"4.1.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>It is unclear which treatment should be given after stopping teriparatide therapy for severe osteoporosis. In a prospective, randomized, controlled, 2-yr study, we compared BMD effects and clinical safety of three follow-up treatments (anabolic with teriparatide, antiresorptive with raloxifene, or no active treatment) after 1 yr of teriparatide. Postmenopausal women with osteoporosis and a recent fragility fracture received open-label teriparatide (20 \u03bcg\/d) for 12 mo before they were randomized (3:1:1) to continue teriparatide (n = 305), switch to raloxifene 60 mg\/d (n = 100), or receive no active treatment for the second year (n = 102). All patients received calcium and vitamin D supplementation. Changes in areal BMD from baseline to 24 mo were analyzed using mixed-model repeated measures. Daily teriparatide treatment for 2 yr significantly increased spine BMD by 10.7%. Patients receiving raloxifene in year 2 had no further change in spine BMD from year 1 (change from baseline, 7.9%), whereas patients receiving no active treatment had a BMD decrease of 2.5% in year 2 (change from baseline, +3.8%). At the total hip, BMD increases from baseline at 2 yr were 2.5% with teriparatide, 2.3% with raloxifene, and 0.5% with no active treatment; the respective changes at the femoral neck were 3.5%, 3.1%, and 1.3%. The study had insufficient power to assess antifracture efficacy. In conclusion, BMD increases progressively over 2 yr of teriparatide therapy in women with severe osteoporosis. After discontinuation of teriparatide, raloxifene maintains spine BMD and increases hip BMD.<\/jats:p>","DOI":"10.1359\/jbmr.081215","type":"journal-article","created":{"date-parts":[[2008,12,2]],"date-time":"2008-12-02T17:32:07Z","timestamp":1228239127000},"page":"726-736","source":"Crossref","is-referenced-by-count":158,"title":["Sequential Treatment of Severe Postmenopausal Osteoporosis After Teriparatide: Final Results of the Randomized, Controlled European Study of Forsteo (EUROFORS)"],"prefix":"10.1093","volume":"24","author":[{"given":"Richard","family":"Eastell","sequence":"first","affiliation":[{"name":"University of Sheffield, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Nickelsen","sequence":"additional","affiliation":[{"name":"Department of Medical Research, Eli Lilly & Company, Europe, Windlesham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Marin","sequence":"additional","affiliation":[{"name":"Department of Medical Research, Eli Lilly & Company, Europe, Windlesham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Barker","sequence":"additional","affiliation":[{"name":"Department of Medical Research, Eli Lilly & Company, Europe, Windlesham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peyman","family":"Hadji","sequence":"additional","affiliation":[{"name":"Klinikum der Philipps-Universitaet, Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Farrerons","sequence":"additional","affiliation":[{"name":"Hospital Santa Creu i Sant Pau, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Audran","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire, Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Boonen","sequence":"additional","affiliation":[{"name":"Katholieke Universiteit Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Brixen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Odense University Hospital, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Melo","family":"Gomes","sequence":"additional","affiliation":[{"name":"Servimed, Lisboa, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Obermayer-Pietsch","sequence":"additional","affiliation":[{"name":"Universitaetsklinik fuer Innere Medizin, Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avraam","family":"Avramidis","sequence":"additional","affiliation":[{"name":"Hippocration General Hospital, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Sigurdsson","sequence":"additional","affiliation":[{"name":"Landspitalinn University Hospital, Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus C","family":"Gl\u00fcer","sequence":"additional","affiliation":[{"name":"UKSH, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"2024020320030922800_bib1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"285","author":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy","year":"2001","journal-title":"JAMA"},{"key":"2024020320030922800_bib2","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"2024020320030922800_bib3","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1359\/JBMR.050309","article-title":"Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters","volume":"20","author":"Arlot","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2024020320030922800_bib4","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1359\/jbmr.2001.16.10.1846","article-title":"Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study","volume":"16","author":"Dempster","year":"2001","journal-title":"J Bone Miner Res"},{"key":"2024020320030922800_bib5","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinte.165.15.1762","article-title":"Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass","volume":"165","author":"McClung","year":"2005","journal-title":"Arch Intern Med"},{"key":"2024020320030922800_bib6","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1359\/jbmr.2003.18.11.1932","article-title":"Teriparatide [recombinant human parathyroid hormone (1\u201334)] improves both cortical and cancellous bone structure","volume":"18","author":"Jiang","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2024020320030922800_bib7","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1210\/er.2004-0006","article-title":"Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use","volume":"26","author":"Hodsman","year":"2005","journal-title":"Endocr Rev"},{"key":"2024020320030922800_bib8","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/01926230252929882","article-title":"Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1\u201334) for 2 years and relevance to human safety","volume":"30","author":"Vahle","year":"2002","journal-title":"Toxicol Pathol"},{"key":"2024020320030922800_bib9","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1001\/archinte.164.18.2024","article-title":"Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis","volume":"164","author":"Lindsay","year":"2004","journal-title":"Arch Intern Med"},{"issue":"S1","key":"2024020320030922800_bib10","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/BF03026325","article-title":"Raloxifene and teriparatide (hPTH 1\u201334) have complementary effects on the osteopenic skeleton of ovariectomised rats","volume":"23","author":"Ma","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2024020320030922800_bib11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/jbmr.5650110205","article-title":"Maintaining bone mass by bisphosphonate incadronate disodium (YM175) sequential treatment after discontinuation of intermittent human parathyroid hormone (1\u201334) administration in ovariectomized rats","volume":"11","author":"Takano","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2024020320030922800_bib12","first-page":"2129","article-title":"Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate","volume":"85","author":"Rittmaster","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020320030922800_bib13","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1359\/jbmr.2001.16.5.925","article-title":"Parathyroid hormone added to established hormone therapy: Effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal","volume":"16","author":"Cosman","year":"2001","journal-title":"J Bone Miner Res"},{"key":"2024020320030922800_bib14","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1007\/s00198-004-1636-z","article-title":"The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide","volume":"15","author":"Kurland","year":"2004","journal-title":"Osteoporos Int"},{"key":"2024020320030922800_bib15","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00198-004-1713-3","article-title":"Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: Treatment and discontinuation of therapy","volume":"16","author":"Kaufman","year":"2005","journal-title":"Osteoporos Int"},{"key":"2024020320030922800_bib16","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1\u201384) for osteoporosis","volume":"353","author":"Black","year":"2005","journal-title":"N Engl J Med"},{"key":"2024020320030922800_bib17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00198-007-0485-y","article-title":"Effect of raloxifene after recombinant teriparatide [hPTH(1\u201334)] treatment in postmenopausal women with osteoporosis","volume":"19","author":"Adami","year":"2008","journal-title":"Osteoporos Int"},{"key":"2024020320030922800_bib18","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","article-title":"Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate","volume":"19","author":"Ettinger","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2024020320030922800_bib19","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1210\/jc.2007-0711","article-title":"Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis","volume":"93","author":"Boonen","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2024020320030922800_bib20","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1359\/jbmr.080506","article-title":"Effects of two years of daily teriparatide treatment on bone mineral density in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment","volume":"23","author":"Obermayer-Pietsch","year":"2008","journal-title":"J Bone Miner Res"},{"key":"2024020320030922800_bib21","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1359\/jbmr.070603","article-title":"Monitoring teriparatide-associated changes in vertebral microstructure by high-resolution CT in vivo: Results from the EUROFORS study","volume":"22","author":"Graeff","year":"2007","journal-title":"J Bone Miner Res"},{"key":"2024020320030922800_bib22","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N Engl J Med"},{"key":"2024020320030922800_bib23","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(97)02342-8","article-title":"Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis","volume":"350","author":"Lindsay","year":"1997","journal-title":"Lancet"},{"key":"2024020320030922800_bib24","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1359\/jbmr.2000.15.5.944","article-title":"Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: Results of a randomized controlled clinical trial","volume":"15","author":"Lane","year":"2000","journal-title":"J Bone Miner Res"},{"key":"2024020320030922800_bib25","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa050157","article-title":"Daily and cyclic parathyroid hormone in women receiving alendronate","volume":"353","author":"Cosman","year":"2005","journal-title":"N Engl J Med"},{"key":"2024020320030922800_bib26","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.081215","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/24\/4\/726\/56575467\/5650240419.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/24\/4\/726\/56575467\/5650240419.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:51:49Z","timestamp":1710341509000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/24\/4\/726-736\/7599951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,1]]},"references-count":26,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[2009,4,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.081215","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2009,4,1]]},"published":{"date-parts":[[2009,4,1]]}}}